Utilization and efficacy of second-line targeted therapy in metastatic renal cell carcinoma: data from a national registry

Overview of attention for article published in BMC Cancer, December 2017

Altmetric Badge

Mentioned by

So far, Altmetric has seen 2 X posts from 1 X users, with an upper bound of 1,039 followers.

Real-world practice 2nd line #mRCC - no significant differences in survival among patients treated with... https://t.co/wtPdH9e5Ln

Real-world practice 2nd line #mRCC - no significant differences in survival among patients treated with everolimus, sorafenib, or sunitinib #kidneycancer @BioMedCentral https://t.co/ioXqz4TyIZ

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity.